Aller au contenu principal
2025 article

Validation of the pathology-adjusted Manchester scoring system in over 10 000 assessments of cases with breast and/or ovarian cancer

1Citations signalées — pas une note de qualité
5Institutions déclarées
1Pays d’affiliation déclarés

Résumé fourni par la source

Background Genetic testing for (likely) pathogenic variants (PVs) in BRCA1 / BRCA2 has been performed in Manchester since 1996, with molecular methods/techniques and eligibility criteria changing over time. In 2004, UK National Institute for Health and Care Excellence guidelines determined a 20% detection threshold, which reduced to 10% in 2013. The Manchester score (MS) was developed in 2004 to assess the likelihood of detecting PVs at the 10%/20% threshold and was updated to include pathology adjustment (2009/17). Current testing algorithms for NHS England are now closer to 5%, although an MS of 15 (=10%) and CanRisk of 10% are still backstop indications. We provide an update of MS on testing of nearly 10 000 breast and/or ovarian cancer (BC/OC) cases. Methods MS using pathology adjustment was applied to cases of non-Jewish BC/OC cases undergoing full screening of BRCA1/2 with testing for CNVs. Results Overall, 6744 BC and 3291 OC cases were tested. For BC, 453 (6.7%) PVs were detected in BRCA1 and 456 (6.8%) in BRCA2 (combined 13.5%). Combined detection with MS=13–14, 15–19 and 20–24 was 52/821 (6.3%), 168/1440 (11.7%) and 193/877 (22.0%), respectively. The MS 15–19 (10%) threshold held true for all age groups and BC pathology types, except grade 1 (very low detection). For OC, detection rates were 273 (8.3%) and 193 (5.9%) for BRCA1 and BRCA2 , respectively. Again, the 10%/20% threshold MS held true with MS=15–19=123/861 (14.3%) and 13–14=22/301 (7.3%). MS=11 gave a robust 5% threshold, although only 1/86 (1.2%) OC <30 years tested positive; this was 1/5 high-grade serous cancers. For sporadic OC >79 years, only 2/177 (1.1%) tested positive. Conclusions MS remains a robust algorithm for assessing likelihood of a BRCA1/BRCA2 PV for individuals with BC/OC.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.

Contrôle bibliographique ouvert

DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.

Titre Crossref
Validation of the pathology-adjusted Manchester scoring system in over 10 000 assessments of cases with breast and/or ovarian cancer
Date Crossref
19/11/2025
Éditeur
BMJ
Type
journal-article

Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude et ne compte pas comme une seconde source scientifique indépendante.

Institutions déclarées

Une affiliation ne permet pas de déduire la nationalité d’un auteur.

Sujets associés

BRCA gene mutations in cancerOvarian cancer diagnosis and treatmentBreast Cancer Treatment Studies

BNTIC News n’est pas le producteur de ces données. Recherche à la demande dans Crossref et Europe PMC, sans clé ; OpenAlex reste optionnel. Aucun service payant requis, aucune réponse conservée. Sources et limites.